Abstract: Provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (i) a step of preparing non-proliferative cells holding a viral peptide antigen, which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by culturing in the presence of the viral peptide antigen and a treatment for causing the cells to lose their proliferation capability; (ii) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (iii) a step of mixing the non-proliferative cells prepared by step (i) with the genetically-modified T cells obtained by step (ii), and co-culturing the mixed cells; and (iv) a step of collecting the cells after culture.

Abstract: In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.

Abstract: The present disclosure includes a method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are normal blood cells that have been engineered to express the target antigen.

Abstract: An object of the present invention is to improve the efficiency of a method for producing chimeric antigen receptor (CAR)-expressing cells. The present invention provides a method for producing genetically modified mammalian cells, comprising the steps of: a) introducing a polynucleotide encoding a chimeric antigen receptor (CAR) protein to a cell population comprising T cells derived from a mammal by a transposon method to obtain a genetically modified cell population; b) providing an endogenous cell population derived from the mammal expressing a protein that binds to the CAR; and c) coculturing the genetically modified cell population of the step a) and the endogenous cell population of the step b).

Abstract: Provided is a composition for lowering blood pressure and/or reducing neutral fat, which composition has few side effects and high safety. The composition for lowering blood pressure and/or reducing neutral fat includes a casein hydrolysate and an indigestible dextrin. Preferably, the casein hydrolysate includes a peptide composed of Met-Lys-Pro. Preferably, the casein hydrolysate includes a peptide composed of Met-Lys-Pro, and a content of the indigestible dextrin is at 5,000 to 100,000 parts by mass with respect to 1 part by mass of the peptide.

Abstract: It is intended to produce a cell expressing a mutant chimeric antigen receptor (CAR) having excellent cytotoxicity to target cells. The present invention provides a genetically modified cell having introduced thereinto a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain, and an intracellular signaling domain, wherein the tar get binding domain is a mutant having the substitution of glutamic acid at position 21 in the amino acid sequence shown in SEQ ID NO: 1 with another amino acid.

Abstract: In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.

Abstract: Provided is a means with which it is possible to efficiently prevent or improve symptoms caused by an imbalance of sex hormones with as little pain as possible, and which can safely be taken daily. A compound selected from the group consisting of a lophenol compound and a cyclolanostane compound is used as an active ingredient of an agent for preventing or improving symptoms caused by an imbalance of sex hormones.

Abstract: Provided is a matrix metalloproteinase production inhibitor which can be daily taken safely. In the matrix metalloproteinase production inhibitor, a compound selected from the group consisting of a lophenol compound and a cyclolanostane compound is used as an active ingredient.

Abstract: The present invention provides: an Aloe vera extract that can be safely ingested, can be used as a material of food for preventing lifestyle diseases, contains an extremely low level of an anthraquinone (anthraquinone-based compound), and can be added to foods; and a method of producing the Aloe vera extract. A supercritical fluid extraction method can produce an Aloe vera extract containing a mixture that consists of a cyclolanostane compound and a lophenol compound in an amount of 1.0% by mass or more and having the following properties (1) and/or (2): (1) the mass mixing ratio of the cyclolanostane compound and lophenol compound is as follows: cyclolanostane compound:lophenol compound=6.3:2.7 to 5.1:4.9; and/or (2) the content of an anthraquinone-based compound is 0.001% by mass or less.

Abstract: An Aloe vera extract is provided that can be safely ingested and, can be used as a food material for treating lifestyle diseases such as hyperglycemia. The Aloe vera extract contains an extremely low level of an anthraquinone (anthraquinone-based compound), and can be added to foods. The Aloe vera extract is produced by a supercritical fluid extraction method and contains a mixture of a cyclolanostane compound and a lophenol compound in an amount of 1.0% by mass or more. The mass mixing ratio of cyclolanostane compound:lophenol compound is 5.1:4.9 to 6.3:2.7 and/or the content of an anthraquinone-based compound is 0.001% by mass or less.

Abstract: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance or ameliorate the pathosis, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant or, a fraction thereof containing the compound as an active ingredient.

Abstract: A curable silicone gel composition that is of low viscosity, exhibits good fluidity, and generates a silicone gel that exhibits good resistance to external stress and thermal stress. The composition includes (A) a specific organopolysiloxane having at least two alkenyl groups within each molecule, (B) an organohydrogenpolysiloxane having a specific branched main chain structure, containing at least three SiH groups within each molecule, and also containing at least one branch-forming unit within each molecule, and (C) a platinum-based catalyst, wherein the cured product has a penetration value of 10 to 200, and loss coefficient values at 25° C. for shear frequency values of 1 Hz and 10 Hz of 0.1 to 1.0 and 0.3 to 1.5 respectively.

Abstract: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant, or a fraction thereof containing the compound as an active ingredient.

Abstract: To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-?-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.

Abstract: 3-O-?-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.

Abstract: Provided is an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and may be used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains a compound selected from a cyclolanostane compound and a lophenol compound as an active ingredient.

Abstract: Compounds having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol are used as an active ingredient of a drug and food or drink for improving pancreatic functions.

Abstract: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.

Abstract: A technique for efficiently performing pulverization of a dried aloe gel using an air flow type mill is provided. 1) A dried aloe gel is treated by supercritical extraction, an extract is removed from the dried aloe gel to obtain an extraction residue, and then 2) the extraction residue is pulverized with an air flow type mill to produce an aloe powder.